PPH: Key Pharmaceutical Innovations Support Bullish Outlook (Upgrade)

VanEck Pharmaceutical ETF is upgraded to Buy, driven by innovation in weight-loss treatments and robust product pipelines among top holdings. PPH's concentrated exposure to Eli Lilly, Merck, and Novo Nordisk provides key catalysts, with LLY's 49% revenue growth and novel obesity drugs leading the charge. Despite industry risks—pricing pressure, patent cliffs, and high R&D costs—PPH's top holdings are mitigating these through diversification and strong product pipelines.

Seeking Alpha • 18 hours ago

Which Healthcare ETF Is the Better Buy: Simplify's Active PINK or VanEck's Pharma-Focused PPH?

Simplify Health Care ETF has a higher expense ratio and a lower dividend yield than VanEck Pharmaceutical ETF. VanEck Pharmaceutical ETF maintains a more concentrated portfolio focused exclusively on global pharmaceutical giants.

The Motley Fool • Oct 11, 2026

Execution of Pharma Tariffs Brings These ETFs Into Focus

Trump's 100% pharma tariff is reshaping the drug industry. Here's how the key pharma ETFs could be affected.

Zacks Investment Research • Oct 6, 2026

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on December 20, 2011.

Zacks Investment Research • Oct 5, 2026

Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP

The VanEck Pharmaceutical ETF offers a lower expense ratio of 0.36% compared to 0.58% for the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF has delivered a higher 1-year total return of 41% relative to 31% for the VanEck fund.

The Motley Fool • Oct 3, 2026

Should You Bet Big on Drugmakers? VanEck Pharmaceutical ETF vs.

The Invesco S&P 500 Equal Weight Health Care ETF provides broader exposure with 60 holdings compared to 26 for the VanEck Pharmaceutical ETF. The VanEck Pharmaceutical ETF currently offers a significantly higher dividend yield and a lower expense ratio than its counterpart.

The Motley Fool • Sep 11, 2026

Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough

Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.

Zacks Investment Research • Sep 1, 2026

FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now

FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.

Zacks Investment Research • Aug 27, 2026

PPH vs. IYH: Which Healthcare Fund Is the Better Buy?

The iShares U.S. Healthcare ETF (NYSEMKT:IYH) provides broad exposure across the healthcare sector, whereas the VanEck Pharmaceutical ETF (NYSEMKT:PPH) concentrates specifically on pharmaceutical stocks. PPH offers a slightly lower expense ratio and a higher dividend yield than IYH.

The Motley Fool • Aug 18, 2026

VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style?

VanEck Pharmaceutical ETF features a lower expense ratio of 0.36% compared to 0.58% for Invesco Biotechnology & Genome ETF. Invesco Biotechnology & Genome ETF delivered a higher 1-year total return of 47.3% but experienced a significantly deeper maximum drawdown of 34.7%.

The Motley Fool • Aug 12, 2026